Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.69 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.58 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.55 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.52 |
| ▸ | GRK2 | P25098 | 1/20 | 0.52 |
| ▸ | GRK3 | P35626 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598434 | 0.87 | IMPDH2 (0.69) | NOTUMROCK2IMPDH2PRMT3ROCK1 | |
| SCHEMBL14625936 | 0.86 | IMPDH2 (0.55) | NOTUMROCK2IMPDH2PRMT3ROCK1 | |
| SCHEMBL3600167 | 0.86 | IMPDH2 (0.74) | NOTUMROCK2IMPDH2PRMT3GRK2 | |
| SCHEMBL3593323 | 0.86 | ROCK2 (0.58) | NOTUMROCK2IMPDH2PRMT3GRK2 | |
| SCHEMBL3593041 | 0.85 | IMPDH2 (0.56) | NOTUMROCK2IMPDH2PRMT3GRK2 | |
| SCHEMBL3590824 | 0.84 | NOTUM (0.60) | NOTUMROCK2IMPDH2PRMT3GRK2 | |
| SCHEMBL3592528 | 0.84 | GRK2 (0.54) | NOTUMROCK2IMPDH2PRMT3GRK2 | |
| SCHEMBL3594471 | 0.83 | IMPDH2 (0.58) | NOTUMROCK2IMPDH2PRMT3GRK2 | |
| SCHEMBL3606333 | 0.83 | IMPDH2 (0.58) | NOTUMROCK2IMPDH2PRMT3ROCK1 | |
| SCHEMBL3596722 | 0.83 | GRK2 (0.54) | NOTUMIMPDH2PRMT3GRK2GRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910297-B1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-1910297-B1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20100093790-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093790-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093790-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090069371-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069371-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069371-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-7470787-B2 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470787-B2 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470787-B2 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070142429-A1 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142429-A1 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142429-A1 | Isoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007008926-A1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069371-A1 | ISOQUINOLINE COMPOUNDS | GNAQ, GRK2, GRK3 | NOTUM 4507/4885ROCK2 70/4885IMPDH2 2567/4885 |
| US-20070142429-A1 | Isoquinoline compounds | GNAQ, GRK2, GRK3 | NOTUM 4507/4885ROCK2 70/4885IMPDH2 2567/4885 |
| US-20100093790-A1 | ISOQUINOLINE COMPOUNDS | GNAQ, GRK2, GRK3 | NOTUM 4507/4885ROCK2 70/4885IMPDH2 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.